Radiation Oncology

Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.

“Far and away, a unified electronic health record is the single use case that could benefit both patients and physicians most, and AI has the potential to help us achieve that,” said Margarita Racsa, MD, MPH.

How do we implement AI in a way that serves patients? Expert radiation oncologists discuss the crucial question.

The regulatory decision for JBS-003 is intended to help guide personalized radiation de-escalation in patients with HPV-positive oropharyngeal cancer.

AI is intended to assist physicians, giving them more time for interpersonal engagement with patients, according to Nevine Hanna, MD, MPH, FACRO, DABR.

New CNS metastasis data link gabapentin to fewer brain mets, spotlight trial barriers, and show promise for intrathecal therapy and osimertinib.

Josef Vymazal, MD, DSc, discusses a prospective study comparing delayed single- and double-dose gadopiclenol MRI for detecting small brain metastases.

The next major problem to tackle for SRS in brain metastases management is how to handle necrosis rates, according to Ayal Aizer, MD, MHS.

Laura Alder, MD, discussed a retrospective analysis evaluating tarlatamab’s efficacy and safety in patients with SCLC and brain metastases excluded from DeLLphi-304.

Laura Alder, MD, discussed how her team at Duke monitors and educates patients for immune-related toxicities while receiving tarlatamab for brain metastases.

Laura Alder, MD, discussed how tarlatamab’s intracranial activity compared with chemotherapy and radiation options for brain metastases in small cell lung cancer.

A new ASTRO clinical practice guideline expands radiotherapy recommendations across resectable, locally advanced, recurrent, and metastatic pancreatic cancer.

A post-hoc analysis of the ARISTOTLE trial demonstrated that patients with rectal cancer with high tumor cell density had improved DFS and OS.

A multidisciplinary panel broke down ILC's distinct biology, imaging challenges, and emerging trial data, including OFSET and SUMMIT.

The phase 2 Neo-CheckRay trial findings showed that adding durvalumab to radiation and chemotherapy nearly tripled pCR rates in PD-L1–negative ER+/HER2− breast cancer.

In a real-world CASCADE database analysis, prophylactic cranial irradiation was associated with a median overall survival of 29.8 months in limited-stage SCLC.

Data from the PSMAddition trial support the approval of the radioligand-based regimen for this prostate cancer population.

Based on phase 2 data, adding consolidative thoracic radiation cannot be recommended outside of clinical trials for unselected patients with ES-SCLC.

A breast surgeon and a radiologist describe the impact the breast biopsy needle shortage has had on their current clinical practice.

Data from the phase 2 RECLAIM trial demonstrate the feasibility of a multimodal strategy in a patient population with limited therapeutic options.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.

Results from cohort C of the TRASTS study showed trabectedin/radiotherapy had positive response rates for patients with resectable retroperitoneal L-sarcomas.

The hypofractionated radiotherapy schedule was noninferior to the standard fractionation schedule regarding HRQOL for patients with cervical cancer.

Efficacy with carboplatin-based induction-concurrent chemotherapy was noninferior to cisplatin, representing a viable alternative for patients with LA-NPC.

Patients with breast cancer and macrometastases who omitted axillary lymph node dissection experienced noninferior survival compared with those who didn’t.